JP6034880B2 - オーロラおよびｆｌｔ３キナーゼモジュレーター - Google Patents

オーロラおよびｆｌｔ３キナーゼモジュレーター Download PDF

Info

Publication number
JP6034880B2
JP6034880B2 JP2014555250A JP2014555250A JP6034880B2 JP 6034880 B2 JP6034880 B2 JP 6034880B2 JP 2014555250 A JP2014555250 A JP 2014555250A JP 2014555250 A JP2014555250 A JP 2014555250A JP 6034880 B2 JP6034880 B2 JP 6034880B2
Authority
JP
Japan
Prior art keywords
compound
hydrogen
kinase
aurora
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014555250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511228A5 (enExample
JP2015511228A (ja
Inventor
チャールズ リーダー，ジョン
チャールズ リーダー，ジョン
Original Assignee
サリウム リミテッド
サリウム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サリウム リミテッド, サリウム リミテッド filed Critical サリウム リミテッド
Publication of JP2015511228A publication Critical patent/JP2015511228A/ja
Publication of JP2015511228A5 publication Critical patent/JP2015511228A5/ja
Application granted granted Critical
Publication of JP6034880B2 publication Critical patent/JP6034880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014555250A 2012-02-06 2013-02-04 オーロラおよびｆｌｔ３キナーゼモジュレーター Active JP6034880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1202027.7 2012-02-06
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds
PCT/EP2013/052182 WO2013117522A1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators

Publications (3)

Publication Number Publication Date
JP2015511228A JP2015511228A (ja) 2015-04-16
JP2015511228A5 JP2015511228A5 (enExample) 2016-03-17
JP6034880B2 true JP6034880B2 (ja) 2016-11-30

Family

ID=45896692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555250A Active JP6034880B2 (ja) 2012-02-06 2013-02-04 オーロラおよびｆｌｔ３キナーゼモジュレーター

Country Status (18)

Country Link
US (1) US9133180B2 (enExample)
EP (1) EP2812328B1 (enExample)
JP (1) JP6034880B2 (enExample)
KR (1) KR102052780B1 (enExample)
CN (1) CN104169277B (enExample)
AU (1) AU2013218167B2 (enExample)
BR (1) BR112014019254B1 (enExample)
CA (1) CA2863759C (enExample)
DK (1) DK2812328T3 (enExample)
ES (1) ES2560260T3 (enExample)
GB (1) GB201202027D0 (enExample)
IL (1) IL233988A (enExample)
MX (1) MX338481B (enExample)
PL (1) PL2812328T3 (enExample)
PT (1) PT2812328E (enExample)
RU (1) RU2643809C2 (enExample)
SG (1) SG11201404277WA (enExample)
WO (1) WO2013117522A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522968B2 (ja) 1987-10-23 1996-08-07 尾池工業株式会社 印刷回路転写箔およびその製造法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JPH06310767A (ja) 1993-04-26 1994-11-04 Nec Corp 寒剤容器の断熱支持構造
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CN1267431C (zh) 2000-06-28 2006-08-02 阿斯特拉曾尼卡有限公司 取代的喹唑啉衍生物及其在制备作为抑制剂的药物中的用途
PL205536B1 (pl) 2000-10-30 2010-04-30 Janssen Pharmaceutica Nv Podstawiona pochodna dihydroindolu, dihydrochinoliny lub dihydroizochinoliny jako inhibitor peptydazy tripeptydowej, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU2003902208A0 (en) * 2003-05-08 2003-05-22 Fujisawa Pharmaceutical Co., Ltd. Inhibitor of cox
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
BRPI0511139B8 (pt) * 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
WO2007043401A1 (ja) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
DE602007009085D1 (de) 2006-05-12 2010-10-21 Ab Science Neues verfahren zur synthese von 2-aminooxazolverbindungen
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8278335B2 (en) 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP2320293A1 (en) * 2009-11-05 2011-05-11 Koninklijke Philips Electronics N.V. Sleep element for improving the sleep of a person
AR079993A1 (es) * 2010-01-12 2012-03-07 Ab Science Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20130231340A1 (en) 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522968B2 (ja) 1987-10-23 1996-08-07 尾池工業株式会社 印刷回路転写箔およびその製造法

Also Published As

Publication number Publication date
DK2812328T3 (en) 2016-01-11
KR20140128373A (ko) 2014-11-05
RU2014131784A (ru) 2016-03-27
HK1204327A1 (en) 2015-11-13
BR112014019254B1 (pt) 2020-03-10
CA2863759A1 (en) 2013-08-15
AU2013218167B2 (en) 2017-04-06
KR102052780B1 (ko) 2019-12-05
EP2812328B1 (en) 2015-11-18
SG11201404277WA (en) 2014-08-28
CN104169277B (zh) 2016-10-12
GB201202027D0 (en) 2012-03-21
RU2643809C2 (ru) 2018-02-06
CA2863759C (en) 2020-04-14
EP2812328A1 (en) 2014-12-17
BR112014019254A2 (enExample) 2017-06-20
US20150018367A1 (en) 2015-01-15
MX2014009323A (es) 2015-04-08
US9133180B2 (en) 2015-09-15
IL233988A (en) 2017-06-29
BR112014019254A8 (pt) 2017-07-11
CN104169277A (zh) 2014-11-26
ES2560260T3 (es) 2016-02-18
MX338481B (es) 2016-04-19
JP2015511228A (ja) 2015-04-16
WO2013117522A1 (en) 2013-08-15
PL2812328T3 (pl) 2016-04-29
AU2013218167A1 (en) 2014-08-14
PT2812328E (pt) 2016-03-01

Similar Documents

Publication Publication Date Title
JP7337133B2 (ja) ＴＡＭおよびＭＥＴキナーゼの阻害薬としてのピラゾロ［３，４－ｂ］ピリジン化合物
JP6402393B2 (ja) 抗悪性腫瘍剤組成物
JP2022508055A (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
CN110036007A (zh) 吡啶化合物
JP2023520330A (ja) 結腸直腸がんに対する前臨床活性を有する発がん性ｃｈｄ１ｌの低分子阻害剤
Zhao et al. Highly selective MERTK inhibitors achieved by a single methyl group
WO2010007374A1 (en) Pharmaceutical compounds
Wan et al. Design and synthesis of fibroblast growth factor receptor (FGFR) and histone deacetylase (HDAC) dual inhibitors for the treatment of cancer
JP2020518595A (ja) 癌、網膜障害及び心筋症の治療のための三置換ピリミジン化合物及び組成物
JP6034880B2 (ja) オーロラおよびｆｌｔ３キナーゼモジュレーター
CN112312901B (zh) Ras癌蛋白抑制剂及其制备方法和使用方法
WO2019157959A1 (zh) 一种嘧啶类化合物、其制备方法及其医药用途
JP2014515026A (ja) アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
KR20240099239A (ko) 결장직장암에 대한 전임상 활성을 갖는 종양원성 chd1l의 소분자
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
RU2720180C2 (ru) Соединения, применяемые в лечении неопластических заболеваний
HK1204327B (en) Aurora and flt3 kinases modulators
WO2025045124A1 (zh) Soat1抑制剂及其应用
CN102485720A (zh) 热休克蛋白90抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161028

R150 Certificate of patent or registration of utility model

Ref document number: 6034880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250